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INTRODUCTION
For some time steroid chemists have known that small chemical changes
in steroid molecules may have profound effects on the biological activity
of a compound. For example, a double bond inserted in the cortisone mole-
cule greatly increases its biological activity as a-1, cortisone (meticorten).
Likewise, removal of a methyl group from progesterone increases its bio-
logical activity, e.g., norprogesterone (Nor-signifying that something has
been removed). In 1954 a group of investigators decided to try to in-
crease the progestational activity of ethinyl testosterone (pregneninolone),
a known potent oral progestogen, by removing this same methyl group.
They succeeded in synthesizing this compound and a closely related one.'
These compounds are known as the 19-nortestosterones (testosterone with
a methyl group removed from the 19 position).
Early evaluation of these compounds disclosed that the predicted increase
in progestational activity was present.'1 Since 1954 a considerable amount
of pertinent information has been published concerning these products.
It is the purpose of this paper to review the literature on these prepara-
tions and to summarize the pharmacological and physiological findings to
date. There are four compounds to be considered:
1. 17a methyl-19-nortestosterone (Neosteron-Organon).
2. 17a ethyl-19-nortestosterone (Nilevar-Searle).
3. 17a ethinyl-19-nortestosterone (Norlutin-Parke-Davis).
4. 17a ethinyl-5(10)-estraen-17,8-01-3-one (Enovid-Searle). Fig. 1.
Progestational Activity
In addition to their obvious structural similarities, these compounds have
several pharmacological properties in common. The foremost of these
properties is their progestational activity. For the most part, these prep-
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arations were evaluated quantitatively in estrogen-primed rabbits (Clau-
berg Test). All four were potent progestational compounds on this test
showing from 2y2 to 25 times the activity of progesterone per os."U17, '0
The compounds showed a greater activity than ethinyl testosterone."
FIGURE I
STRUCTURAL RELATIONSHIPS OF TESTOSTERONE.PROGESTERONE
AND FOUR COMPOUNDS WITH PROGESTIONAL ACTIVITY.
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When the compounds were administered parenterally, there was decreased
progestational activity. The compounds showed activity varying from less
active to 10 times as active as progesterone.'" When administered directly
into the uterus of the rabbit, the compounds showed less than one-fourth
the activity of progesterone, probably indicating that some product of
metabolism is the active hormone.'" Carbonic anhydrase studies in rabbit
endometria, as a measure of progestational activity, showed rather unim-
pressive results, and mucus changes were atypical." It is not possible to
project the results of such animal experiments directly to man.
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All four compounds have exhibited some degree of progestational activity
in the human, the drugs showing a greater advantage over progesterone
when administered by the sublingual and oral routes.7'9'1"'' One compound,
17a methyl-19-nortestosterone (Neosteron), shows 150 times the potency
of progesterone and 50 times that of ethinyl testosterone when administered
sublingually.7 Parenterally, this great advantage over progesterone is lost,
the effects ranging from 10 times the magnitude to less activity than pro-
gesterone administered by the same route.9 The drugs produce definite
endometrial changes resembling those of progesterone.7' 1'X X" However,
Southam and Pincus found that in their patients there was a greater effect
on stromal cells than glandular epithelium.=" Basal body temperature is
elevated by administration,9" and there appear to be typical progestational
cervical mucous changes."'9 Withdrawal bleeding occurs with all four drugs
in estrogen-primed women."' The exact status of withdrawal bleeding
caused by these compounds is rather confused since three of the compounds
are known to be contaminated with estrogen. "" X 2 Alkaline phosphatase
studies show changes more consistent with proliferative stages than with
true secretory endometrium.' These studies would indicate that there is
a distinct possibility of some variation from true progestational activity.
Prolonged administration of two of these compounds has demonstrated
excellent decidual response in both human and monkey endometria.19 2' " '
Androgenic Activity
Two of the compounds, 17a methyl-19-nortestosterone (Neosteron) and
17a ethyl-19-nortestosterone (Nilevar), as might be expected from their
derivation, show androgenic activity.3'7' "'' In rats, this amounts to about
6 per cent of the activity of testosterone proprionate."'7 One author failed
to find any androgenicity in the rat.8 It appears that these compounds have
considerably less androgenic effect in humans than does testosterone.=
Since esters of 19-nortestosterone exhibit quantitatively different andro-
genic activities,"
" " it is possible that as different esters of these com-
pounds are investigated, similar changes will be demonstrated.
Anabolic Activity
The above-mentioned compounds, despite their rather poor androgenic
activity, exhibit profound anabolic and myotrophic effects in animals.8' B'
r
In studies on the levator ani muscle of rats, activity similar to testosterone
propionate is noted." In the human, this anabolic and myotrophic effect
is less easily demonstrated. Ferrin7 showed no anabolic effect in humans
with the methyl product (Neosteron), and Sachs' and Spencer8' showed
varying amounts of anabolic activity with the ethyl product (Nilevar).
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Reproduction
There has been much interest in the effect these compounds have on the
physiology of reproduction. They have multiple actions in preventing con-
ception. All four compounds inhibit ovulation both in animals and hu-
mans."' If ovulation does occur, there is some evidence that corpus
luteum function is too poor to support a subsequent pregnancy.' This
action may be due to either a direct effect on the ovary, or to secondary
ovarian response to decreased gonadotrophin production. However, in
most cases the ovulation response seems to precede and outweigh any
measurable depression of the gonadotrophin titers. There is also some
evidence that at least one of the compounds may have a damaging effect
on any ovum that may be fertilized.'7 Heller,'0 in a controlled series of
human experiments, has demonstrated that these compounds, as well as
progesterone, cause complete azoospermia, although there may be some
residual spermatogenesis in biopsy specimens. The compounds support
pregnancy poorly. Pincus' claims that the ethyl compound (Nilevar) is
a "potent maintainer of implantation." However, Saunders and Drill2"7
have shown that this compound is only 25 per cent as effective as proges-
terone in maintaining pregnancy. 17a ethinyl-5(10)-estraen-17,8-01-3-one
(Enovid) even seems to antagonize exogenous progesterone in its ability
to maintain pregnancy.'
The decidual response shown by these drugs has been utilized by Rock
et aL to produce a so-called pseudo-pregnancy and "rebound."""' The
drugs were administered through two or more succeeding cycles with re-
sultant amenorrhea and symptoms of early pregnancy. Rock noted that
after cessation of therapy, a significant number of pregnancies occurred.
Southam,T however, in a similar experiment demonstrated that the same
degree of "rebound" could be obtained with progesterone and, in fact, the
number of pregnancies after the "rebound" probably was not significantly
higher than the number to be expected in an untreated series followed for
a similar length of time.
Estrogenic Activity
All the compounds have some degree of inherent estrogenic activity be-
sides the estrogen contamination mentioned earlier. The effect in the
methyl (Neosteron) and ethyl (Nilevar) compounds is probably negligi-
ble,"'' the ethyl product (Nilevar) showing some anti-estrogenic activ-
ity."5 The ethinyl product (Norlutin) exhibits some definite estrogenic
effects in rat experiments, and in humans probably causes some minimal
estrogenic effect."'27 Jadrijevic et al." have demonstrated some anti-
estrogenic activity in the guinea pig. The estrogenic effects of 17a ethinyl-
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5(10)-estraen-17,/-01-3-one are high enough to be of significance in hu-
mans, and quantitation in animals shows it to have 1 to 7 per cent the
activity of estrone sulfate." Since this estrogenic activity is even higher
in the commercially available contaminated product (Enovid), the manu-
facturers have added estrogen to try to eliminate any break-through
bleeding.
Effects on Gonadotrophin
In animals the compounds exhibit gonadotrophin-inhibiting activity.8"1
This inhibition is less definitely established in humans. The antigonado-
trophic effect is not related to the androgenicity of the compounds.8
Metabolism
The intermediary metabolism of the four compounds is unknown. The
knowledge of their effect on intermediary metabolism is equally sketchy.
They show no effect on survival of adrenalectomized rats.' The ethyl com-
pound (Nilevar) increases the serum a2 and /8 globulins and the /8 lipo-
proteins.' They produce relatively poor sodium retention.1' The urinary
pregnanediol levels are unaffected, as are the 17-ketosteroids and 17-OH-
steroids, according to Greenblatt. However, Pincus' claims a decrease
of these same steroids. He also reports a decrease in blood progesterone
levels and changes in the protein-binding of 17-OH-steroids. 19-nortes-
tosterone has exhibited some very interesting adrenal protective reactions,m
but thus far no such activity has been demonstrated for the progestational
compounds.
Toxicity
Long-term administration of the compounds to both animals and humans
shows no evidence of toxicity of permanent anatomical or physiological
change.17'' However, Rock' does raise a question of damage to the
primordial follicles. Side effects are not remarkable. Nausea, drowsiness,
and anorexia are the principal untoward reactions,"' and occasional skin
reactions have been reported.
SUMMARY
There are, therefore, four new synthetic compounds with the possibility
of an infinite number of esters exhibiting progestational, myotrophic, and
either androgenic or estrogenic activity (Table 1). At the present time
it would seem that the compounds are probably more important from the
standpoint of their chemical structure and the possibility that their small
variations from the activity of progesterone may offer clues as to the func-
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tion of various portions of the progesterone molecule. For the clinician,
their advantage over the existing progestational compounds is less easily
shown. 17a methyl-19-nortestosterone (Neosteron) would seem to offer
a good progestational compound with minimal androgenicity. (The clini-
cal studies on this compound have been done mainly in Europe and are
less well known than on the other compounds). 17a ethyl-19-nortestos-
TABLE I
THE BIOLOGICAL ACTIVITY OF FOUR 19-NORTESTOSTERONES.
PROGESTICNDANDROEC ESTROGENIC MYOTROPHIC INHOTION OF CONTRPTION SIDE
EFFECT EFFECT EFFECT EFFECT GONADOTROPIN EFFECTS.
17aw. METHYL
I ++++ ++ _ +++ + ++++ +
(NEOSTERON)
17ac ETHYL-
19NtEOSERONE + + + + - ++++ +++ + +++ + +
(NILEVAR)
17oe- ETHINYL-
19NOrFESTCE ++++ - ++ _ + ++++ +++
(NORLUTIN)
17.c ETHINYL-500)
ESTRAEN rrrLm- 3 +++ +- ++.+ +- ++++ ++++ ++++
ONE (ENOVID)
terone (Nilevar) would seem to be the best anabolic agent of the four, with
rather poor ability to prevent break-through bleeding and minimal andro-
genic activity. 17a ethinyl-19-nortestosterone (Norlutin) and 17a ethinyl-
5(10)-estraen-17,8-01-3-one (Enovid) demonstrate good progestational
activity with minimal anabolic activity. However, both have definite estro-
gen effects. This has been compensated to some extent in Enovid by the
addition of estrogen, so administration of the compound is essentially com-
bined estrogen-progesterone therapy (Table 1).
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